Biomarkers /
BCL2L11
Overview
BCL2L11 is altered in 0.44% of all cancers with prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in BCL2L11 are BCL2L11 Mutation (0.28%), BCL2L11 Loss (0.07%), BCL2L11 R153W (0.02%), BCL2L11 Amplification (0.02%), and BCL2L11 E176K (0.01%) [3].
Clinical Trials
Significance of BCL2L11 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.